TFS Capital’s Orexigen Therapeutics, Inc. OREX Stock Holding History

TFS Capital’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-1,709	Closed	-$36K	–	1115
2015 Q3	$36K	Buy	+1,709	New	+$58.6K	﹤0.01%	861
2015 Q2	–	Sell	-2,497	Closed	-$196K	–	1297
2015 Q1	$196K	Buy	+2,497	New	+$155K	0.02%	781

Other funds holding OREX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TFS Capital's OREX Position: Q4 2015 in Review

TFS Capital sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2015, closing a stake of 1,709 shares — an estimated $36K sold.

TFS Capital first reported a position in OREX in Q1 2015 and held it in 2 quarters. The position peaked at $196K in Q1 2015. 121 funds tracked by Wall St. Rank hold OREX as of Q4 2015.

TFS Capital reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
TFS Capital sold 1,709 Orexigen Therapeutics, Inc. shares in Q4 2015, an estimated $36K.
TFS Capital first reported a position in Orexigen Therapeutics, Inc. in Q1 2015 and held it in 2 quarters.
TFS Capital's Orexigen Therapeutics, Inc. position peaked at $196K in Q1 2015.
121 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2015.

Based on TFS Capital's 13F filing for Q4 2015, filed 29 Jan 2016.